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A Novel Approach to Detecting Epistasis using 
Random Sampling Regularisation 
 
Jade Hind, Member, IEEE, Paulo Lisboa, Senior Member, IEEE, Abir J. Hussain, Member, IEEE,  
Dhiya Al-Jumeily, Senior Member, IEEE 
Abstract— Epistasis is a progressive approach that complements the ‘common disease, common variant’ hypothesis that highlights the 
potential for connected networks of genetic variants collaborating to produce a phenotypic expression. Epistasis is commonly performed as a 
pairwise or limitless-arity capacity that considers variant networks as either variant vs variant or as high order interactions. This type of 
analysis extends the number of tests that were previously performed in a standard approach such as Genome-Wide Association Study (GWAS), 
in which False Discovery Rate (FDR) is already an issue, therefore by multiplying the number of tests up to a factorial rate also increases the 
issue of FDR. Further to this, epistasis introduces its own limitations of computational complexity and intensity that are generated based on 
the analysis performed; to consider the most intense approach, a multivariate analysis introduces a time complexity of O(n!). Proposed in this 
paper is a novel methodology for the detection of epistasis using interpretable methods and best practice to outline interactions through 
filtering processes. Using a process of Random Sampling Regularisation which randomly splits and produces sample sets to conduct a voting 
system to regularise the significance and reliability of biological markers, SNPs. Preliminary results are promising, outlining a concise 
detection of interactions. Results for the detection of epistasis, in the classification of breast cancer patients, indicated eight outlined risk 
candidate interactions from five variants and a singular candidate variant with high protective association.  
Index Terms—GWAS study, SNPs, Artificial Intelligence, genome, logistic regression.    
——————————      —————————— 
1. INTRODUCTION  
Breast cancer is a complex disease; multifactorial effects repre-
sent the phenotypic response of the subject. While there is cur-
rently an abundance of techniques for the analysis of genetic 
data, there is still a limited contribution of reproducible genetic 
signals that provide evidence of association with sporadic breast 
cancer. This study aims to investigate the interactions that exist 
in subjects associated to breast neoplasms in invasive breast can-
cer. By considering a representative set of Single nucleotide pol-
ymorphisms (SNPs) from the genome, further analysis can be 
conducted from genome-wide analysis to suggest potential SNPs 
for interactions.  
Current efforts in breast cancer have led to early screening, with 
great successes in reducing the number of advanced cases. Fur-
ther to this, the introduction of genetic knowledge also outlines 
patient and their family for potential susceptibility to cancer 
through examples of the BRCA1 and BRCA2 gene. These 
measures provide a preventative outlook for patient health, a 
leading direction to personalised medicine that will address pa-
tients on an individual basis taking into consideration factors 
such as genetic make-up. The identification of these SNPs could 
lead to the classification of susceptible breast cancer patients and 
potentially the pharmacological or therapy treatments that are 
most suitable for these individuals.  
Progressive approach epistasis, invites new avenues of research. 
The phenomenon that suggests combinations of biological mate-
rial such as SNP variants are working as a system or network to 
produce the phenotypic outcome is becoming a favorable lead. 
Given the elusiveness of genetic causation in the face of high 
heritability, epistasis suggests an enigmatic genetic component is 
not being detected as the signal for networks of SNPs are mask-
ing one another. Therefore the research subject of epistasis in-
vites a new problem area to explore. Current practices in epistasis 
detection range from pairwise to exhaustive search criteria; the 
limiting nature of pairwise detection could lead to loss of infor-
mation by oversight however exhaustive search present their own 
problems with the demand for computational power. 
To address the current issue of computational complexity, our 
method proposes a multidimensional reduction technique that re-
lies on the strong presence of SNPs (Single Nucleotide Polymor-
phisms) across multiple panels of subjects with the objective be-
ing to outline prominent SNPs with unyielding presence among 
the panels. Considering the current limitations of epistasis, a pro-
gramme that employs a limitless-arity approach is utilised to 
identify relationships between SNPs. Further analysis investi-
gates the true significance of these associations, adopting a vari-
ety of robust statistical techniques that overcome issues that are 
common in predictive algorithms, such as overfitting. Described 
in this paper are the problems further defined and the chosen so-
lutions to address these issues within the proposed methodology. 
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2. BACKGROUND AND RELATED WORKS 
The analysis of genomic data is providing individuals with infor-
mation and knowledge to take control of their health [1]; while 
still in its early stages, genomic analysis and its resulting out-
comes can aid the healthcare sector, approaching the much de-
bated subject of personalised medicine [1]. Personalised medi-
cine caters for the needs of patients by considering their biologi-
cal and epidemiological make-up. This will in future replace the 
current “one-size-fits-all” approach that is common in prescrip-
tion medication; an individual’s biological make-up could pro-
vide information for the most appropriate treatment response, i.e. 
indicating the amount, variety and response to particular drugs 
[2]. This is important in complex diseases as treatment is often 
based on a necessary ‘trail-and-error’ period which may or may 
not provide relief from the symptoms [3]. Further to this, even t 
reatment options that aid in reducing or eliminating the problem-
atic symptoms of a disease or disorder, can also cause a variety 
of side effects that can still effect patients Quality of Life [4][7] 
[5]. 
There are several approaches to genomic study which are com-
monly used to identify risk variants in common, complex dis-
eases such Breast Cancer; GWAS (Genome-wide Association 
study), Candidate Gene and Familial studies. One of the most 
popular genetic feature inputted for study analysis are SNPs (Sin-
gle Nucleotide Polymorphisms), these are variants in base pairs 
within the DNA sequence [8] [6]. While a majority of these SNPs 
will have little to no impact on the biological systems, the conse-
quential causal sequence can lead to imbalances in chemicals, 
misfolds in protein polypeptide chains and instability in mRNA 
transcripts [9] [11-15]. The involvement of these SNPs in the ge-
netic analysis for the purpose of finding risk variants is due to the 
abundance of variation throughout the genome; proving promis-
ing and successful in many determined diseases so far 
[9][10][16]. Although there are many other genetic and biologi-
cal studies that are successfully undertaken, the following iden-
tified approaches utilise the SNP feature input for the analysis of 
correlation and susceptibility in subjects. As such, the following 
sub-sections encompass the approaches to data analysis that con-
sider the variability that exists in genomics due to the structure 
of genetic data and the subject specification. 
2.1 Genome-Wide Association Studies 
Genome-Wide Association Studies (GWAS) provides a way in 
which the whole genome (genotyped SNPs) can be scanned to 
identify SNPs that confer risk for the identified and analysed phe-
notype. Presenting a hypothesis-free approach that has intro-
duced an option for researchers to visualise whole genome ef-
fects for diseases. 
The most common approach in GWAS utilises a case-control set-
up [17]; Cases refer to a cohort affected by the disease subject of 
the study and Control refers to a cohort who are unaffected by 
the disease. The proceedings of a GWA study aims to find the 
correlation results between the cohorts and the disease. In an or-
dinary case-control GWAS, the odds ratio is the first considered 
statistics in which an OR > 1 suggests the association of an allele 
is a risk for disease, the greater the difference from 1, the more 
indicative of an association and an OR < 1 suggests a protective 
association against a disease [10].  Performing a chi-squared test 
from the results will provide significance of the alleles associa-
tion; that is, how likely it is that the result is truly associated with 
the disease.  
While GWAS presents a unique approach for analysis of genetic 
material, its requirements introduce both advantages and disad-
vantages. GWAS have also previously been acknowledged for 
their expense; however, this criticism is becoming obsolete as 
advances in technology are reducing the costly price [18]. This 
approach also outlines some disadvantages that effect the relia-
bility of the study such including high false discovery rate and 
the overlooking of rare alleles which could potentially be im-
portant to the discovery of biomarkers [19]. As such, an im-
portant feature of GWAS are the requirements for a large sample 
size for reliability of result outcomes [28]. Unfortunately, this ac-
commodation does not rectify the issues that are present with 
false discovery in GWAS and given the parameters that define 
the size of these studies, transfer learning is commonly adopted 
from methods that aim to reduce, rectify and eliminate the effects 
of bias and false discovery in ‘Big Data’. A common approach 
from big data techniques is to use multiple testing adjustments, 
as discussed later on in Methodology. Successes in GWAS have 
previously outlined viable SNPs in complex diseases such as 
Crohn’s Disease [29], Rheumatoid Arthritis [30-33] and Celiac 
Disease [34].  It has also previously been proposed that GWAS 
studies should be a first step in the genetic identification process 
[43]. 
Within the next section, the focus moves to an approach that con-
trasts with the whole-genome approach of GWAS to introduce an 
approach that focuses its efforts in areas of significance based on 
prior knowledge. 
2.2 Breast Cancer  
Cancer is a global concern, with prominent mortality rates across 
the board demonstrated by its current position as second leading 
cause of death in the United States, 2016 [45]. In 2016, 11,563  
deaths were reported due to Breast Cancer,  with increasing inci-
dence rates that resulted in approx. 55,000 new cases in 2015, for 
England alone [48].  The current survival rate for Breast Cancer 
in England is 78%, however this is highly related to screening 
practices that are in place for quick diagnosis, ensuring treatment 
is started as soon as possible [48].  
The symptoms of breast cancer vary, and quite often are due to 
common occurrences in the body that are unrelated to the devel-
opment of cancerous cells. Current campaigns urge women to 
regularly check the size, shape and feel of breasts to be aware of 
changes that are associated with breast cancer. Lumps, breast 
pain, changes in skin colour and texture, abnormal discharge and 
inverted or sunken nipples encompass the most common symp-
toms associated with Breast Cancer [49].  
Breast cancer is most curable in its early stages which empha-
sises the importance of the screening processes that are in place.  
Diagnosis of breast cancer is most commonly conducted using 
imaging techniques including mammograms and ultrasound 
[50]. Diagnosis of breast cancer normally adheres to a ‘two-week 
wait’ protocol that insists that suspected cancer patients are first 
seen by a specialist within 2-weeks [51]. With this protocol in 
place, ~90% of cases with known stage are diagnosed with early 
stage breast cancer (Stage 1 & 2, discussed later) [48].  
Breast Cancer is divided in to 4 stages that are based upon the 
TNM staging system. The TNM system uses information about 
the tumour size, node spread and metastasis status to assign a 
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stage to a case. Genetic predisposition to breast cancer is fast be-
coming a common practice in aiding both the diagnostic and pre-
ventative measures for Breast Cancer[52], [53]. One of the most 
commonly associated but rare genetic associations in breast can-
cer is the BRCA1 and BRCA2 genes; these are inherited genes 
that express a predisposition to breast cancer in 15% of familial 
cases; presenting a 50-85% increased risk in women. BRCA1 an 
BRCA2 presents the highest penetrance in familial cases of 
breast cancer, however several genes have been indicated to pre-
sent a percentage of penetrance for familial breast cancer but 
does not explain all [54].  
Familial studies encompass the vast majority of successful ge-
netic discoveries in breast cancer with emphasis being placed in 
the now well-known BRCA1 and BRCA2 genes. There are cur-
rently three established categories of mutations defined as high 
penetrance, moderate-risk and low-risk. These categories cur-
rently include a number of genes indicated in research including 
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, 
FANCM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, 
PALB2, PMS1, PMS2, PTEN, RAD50, RAD51C, STK11 and 
TP53 genes [54] [55] [20-27]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As a high penetrance mutation, the BRCA1 gene was first local-
ised in 1990 by Hall et al. [60] who utilised logarithm of the like-
lihood ratio for linkage, or better known as ‘Lod’, to ascertain a 
likelihood ratio ranging from 2000:1 and 1.4×106:1 among the 
23 tested families within the study [60]. From this, further studies 
were performed, leading to the discovering of the BRCA2 gene 
by Wooster et al. [61], using similar techniques. Table I provides 
approximate estimates for penetrance and relative risk of high 
and moderate penetrance SNPs [54], [56-59]. 
2.3 Epistatic Studies 
Epistasis association is a developing technique that investigates 
the role of multiple genetic signatures in respect to the disease, 
suggesting the interacting components produce the phenotypic 
expression commonly associated with the disease. Breast cancer 
has received a lot of attention using the epistasis technique within 
the past 10 years. However, having been subject to the limitations 
of epistasis, studies have been focusing their effort on smaller 
sets of biologically related gene or prior knowledge from previ-
ous studies [62].  
The limitations of this study type result in many epistasis studies 
focusing on a dramatically reduced set of SNPs or using a limited 
2-way interaction model that only considers the interactions of 2 
SNPs in relation to the phenotype. A large-scale analysis of 
~89,000 subjects and 75,380 SNPs previously identified via 9 
GWAS studies encompassing 10,052 cases and 12575 controls 
was conducted using two-way SNP interactions [63]. This study 
yielded few SNPs that exceeded the genome-wide threshold of 
1×10-8 but concluded more SNPs with 1×10-6. Further studies 
have been conducted in association with Breast Cancer, using re-
duction parameters for SNP dimension such as pathway analysis. 
Pathway analysis considers the pathology of the disease and uses 
these genetic signatures to conduct an epistasis study. Using 
DNA repair, modification and metabolism related pathways, 
Sapkota et al [64] identified 2-way SNP interactions that yielded 
a result of <7.3×10-3, however this again uses a two-way interac-
tion model which may not confer the risk that is associated with 
a group of interacting SNPs across genes or chromosomes. 
2.4 Data Description 
Subject genotypes were attained from repository platform, Data-
base of Genotypes and Phenotypes (DBGaP). Data was collected 
under the Genetic Associations and Mechanisms in Oncology 
(GAME-ON) initiative that funded 5 projects, one of which was 
the Discovery, Biology, and Risk of Inherited Variants in Breast 
Cancer (DRIVE) project that focused its efforts in breast cancer 
for the systematic discovery and replication of additional com-
mon genetic variants. These variants were assessed for their bio-
logical significance and from this, developed evidence-based as-
sessments of the clinical validity of prediction algorithms in 
practice. 
Genotyping was conducted by the Center for Inherited Disease 
Research (CIDR), Centre for Cancer Genetic Epidemiology, 
University of Cambridge, and the National Cancer Institute. The 
following studies, used within this study, contributed germline 
DNA from breast cancer cases and controls:  
 Copenhagen General Population Study (CGPS)  
 Cancer Prevention Study 2 (CPSII)  
 Melbourne Collaborative Cohort Study (MCCS)  
 Multiethnic Cohort (MEC)  
 Nurses Health Study (NHS)  
 Nurses Health Study 2 (NHS2)  
 Women of African Ancestry Breast Cancer Study (WAABCS) 
 Women's Health Initiative (WHI) 
With Breast Cancer incidence rates primarily effecting the fe-
male population, the study cohort is made up entirely of female 
participants (n = 28,281). Of these participants 14,435 subjects 
were cases and 13,846 were controls. Age ranged from 20 to 98 
(µ = 63) based on a sample of 27,585 with age ranging from 20 
to 92 (µ = 65). Cases were split into 3 histology types, invasive 
(12,412), in-situ (1,506) and unknown (517) of which, individu-
als of interest in this research are invasive histology type. Inva-
sive breast cancer status regards cancer cells that have at least 
‘spread’ to the surrounding breast tissue. 
3. TECHNIQUES AND METHODS 
3.1 Proposed Methodology  
 
Random Sampling Regularisation is our proposed methodology 
that aims to improve selection criterion for epistasis, reduce false 
TABLE I: PENETRANCE LEVEL OF ESTABLISHED SNPS ASSO-
CIATED WITH BREAST CANCER  
High Penetrance Gene Incidence 
 BRCA1 82% lifetime risk 
 BRCA2 82% lifetime risk 
 PTEN 85% lifetime risk 
 TP53 25% by age 74 
 CDH1 39% lifetime risk of lobular breast can-
cer 
 STK11 32% by age 60 
   
Moderate Risk Gene Risk in Females (RR)a 
 CHEK2 1.7 
 BRIP1 2.0 
 ATM 2.37 
 PALB2 2.3 
a
 RR; Relative Risk   
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discovery and cater for non-intensive computational require-
ments. The proposed method consists of 6 stages described as 
follows.  
A. Stage 1: Quality Control (QC) 
The proposed methodology adheres to standard practices in 
GWAS [66][67]; adopted in many studies [65][60] employing 
standard processes; ancestry divergence, sex inconsistencies, 
heterozygosity, relatedness and duplicates in subjects, Linkage 
Disequilibrium (LD) pruning and common threshold measures, 
Minor Allele Frequency (MAF), and Genotype rate (GENO). 
Conservative threshold measures are applied to create a reliable 
dataset that is devoid of missing values and information that 
could cause errors later [35-42].  
Table II records the number of removed observations and fea-
tures after each step has been performed and provides a break-
down of the processes. The remaining dataset is comprised of 
13,649 (7,136 cases) (6,513 controls) observations and 320,247 
features, or SNPs. 
 
TABLE II: QUALITY CONTROL PROCESS EXCLUSION VALUES 
Process Removed Remaining 
 Subjects Variants Subjects Variants 
Before QC 
  
28281 528620 
Ancestry Divergence 675 - 27606 - 
Related and Duplicates 7750 - 19856 - 
Heterozygosity 301 - 19555 - 
Sex Inconsistencies 72 - 19483 - 
Linkage Disequilibrium Pruning - 116115 - 412505 
Threshold Measures     
Missingness in Individuals 4399 - 15084 - 
Genotype Call Rate - 21561 - 390944 
Hardy Weinberg Equilibrium - 1269 - 389675 
Minor Allele Frequency - 69428 - 320247 
Missing Phenotype 1355 - 13729 - 
Exc. Crit: Age < 40 80 - 13649 - 
After QC   13649 320247 
B. Stage 2: Cohort Extraction 
To respond to the common issues that are present in GWAS’s, 
the cohort extraction is a preliminary stage in Random Sampling 
Regularisation to extract random cohorts of individuals that can 
represent a real-world sample cohort for analysis. Using this 
method, the data is prepared to explore in later stages if a con-
stant effect is common across significant SNPs (which it should 
be if it is truly associated). Further to this, the effect of population 
structure is evident in many studies; this is a difficult problem to 
solve unless the study data has been obtained from a purpose 
built clinical study. Therefore, the randomisation of the data can 
disperse the effect of the population structure among the cohort 
to reduce the effects. Having performed QC, excluding any out-
lier subjects and/or SNPs, in a standard GWA study the remain-
ing subjects are used to perform an association analysis to pro-
vide a resulting set of SNPs with their corresponding p-values to 
indicate the probability of significance to the phenotype.  
C. Stage 3: Association Analysis 
Association analysis models vary in the outcome information, 
this puts importance on choosing the most appropriate model for 
the approach . As further analysis is used to investigate the infor-
mation beyond this point, there is affordance to use the allelic 
model analysis and gain the benefits of the increased statistical 
power. During this stage, multiple testing is not utilised but will 
be addressed in later stages, however genomic control is used to 
control for population structure. 
D. Stage 4: Feature Selection  
This stage uses the results of the association analysis to produce 
a subset of features that show significant association to the given 
phenotype. The results from the association analysis are com-
bined to produce a mean gc-value and the corresponding stand-
ard deviation which will provide information as to how much the 
value is shifting across the subset cohorts. This will provide in-
formation as to whether the SNP is consistently associated with 
the phenotype or is falsely associated with a sample of subjects. 
Continuously mentioned in literature, is the ‘statistical power’ of 
a study, within genomic studies it is generally accepted that the 
bigger the cohort the less likely a SNP will show false associa-
tions; this is due to the normalisation of data with the addition of 
more observations.  While this is true, consider that the number 
of features that are tested during genomic studies is large and as 
a result the likelihood of producing a false positive is also in-
creased. By splitting the cohorts into n×n sections, our sample 
size is improved by n times.  
E. Stage 5: Epistasis   
The purpose of this stage is to sift through the combinations of 
SNPs to outline potentially significant relationships for further 
analysis.  The use of a software programme that employs a lim-
itless arity approach produces exhaustive results that investigate 
the relationships that exist between all combinations (excluding 
those eliminated during reduction techniques) and the focus phe-
notype. This benefits the methodology as it considers a larger 
feature set that would otherwise be impractical to explore via 
normal statistical techniques. We have chosen to use LAMPlink 
due to the benefits of limitless arity with the additional benefit of 
speed. Acknowledging the use of a dominant model leads to sac-
rificing potential combinations, the purpose of the method is to 
explore the effects of using random sampling regularisation to 
produce a set of resulting candidates while reducing FP and FN 
error rates. 
LAMPlink provides a method of detecting significant associa-
tions using a large number of features. Generally epistasis pro-
grammes will perform epistatic interaction tests using two-way 
feature sets e.g. PLINK; this significantly reduces the explora-
tory power of epistasis by by-passing the potential for component 
clusters of 3 or more features. LAMPlink tests the potential of 
every possible combination while reducing the number of tests 
performed by adjusting the number of SNPs based on [4] com-
plexity correction. This significantly reduces computational 
complexity and also reduces the time consuming process that is 
generally associated with epistasis approaches. The following 
section outlines the process of LAMPlink. 
F. Stage 6: Inference Analysis   
During this stage, the relationships outlined by LAMPlink are 
further analysed. As LAMPlink is only used to outline the poten-
tial relationship, this stage is used to expand the relationships 
outlined and to further analyse them to confirm or disregard the 
findings. Relationships that adhere to the petal plot policy will be 
extracted from the training set, with allelic and genotypic states 
combinations explored; as all combination states would be ex-
haustive to perform manually. During stage 6, interaction rela-
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tionships outlined by LAMPLINK are further analysed. Combi-
nations including singular, two-way and three-way along with all 
possible combination states (excluding combinations that do not 
contain more than 10 values in one cell of case-control based 
contingency table) are analysed to expand and explore the rela-
tionships outlined during the previous stage. In order to outline 
the most significant relationships, all combinations having suc-
cessfully been analysed using the test dataset will be further an-
alysed for their relationship to breast cancer in terms of pene-
trance, incidence and risk. 
 
Penetrance (Pe): How many subjects have been affected by the 
phenotype that also carry the genomic interaction state? 
( | )
a
P Phenotype Genotype
a b


 
Incidence(I): What percentage of the sample population carry 
this genomic interaction state? 
( | )
a b
P Phenotype SamplePopulation
n

  
Risk (OR): How strongly associated is the presence of the 
genomic interaction state with the presence of the phenotypic 
state? 
odds of disease among exposed ad
odds of disease among unexposed bc
  
 
These measures will provide a real-world understanding of how 
this information relates to breast cancer and what the resulting 
combinations indicate statistically. 
 
3.2 Evaluation and Validation 
 
Each aspect of this methodology has carefully considered and 
serves a purpose for filtering and extraction of features of signif-
icance approaching the problem for the detection of epistasis. 
The methodology aims to address a series of issues as shown in 
Table III.  
 
TABLE III: BENEFITS OF THE PROPOSED METHODOLOGY. 
Reducing FDR 
Stage 2 introduces the first stage that aims to address the issue of FDR by tackling 
the problem before it occurs. Finalising in Stage 3 using multiple association anal-
ysis to build a picture of how genetic component behaves among varying sample 
populations. 
Computational expense 
Exhaustive Epistasis searches requires extended time allowances or require sub-
stantial hardware for processing. This method aims to outline a representative set 
of SNPs that do not require substantial hardware but is a small enough set of 
representative SNPs that epistasis can be performed on in a reasonable time con-
straint. 
Improvement of epistasis detection 
One of the most challenging problems in epistasis is the detection of interactions 
while accounting for the influencing pitfalls of FDR, computational complexity 
and the statistical filtering that is commonly used to reduce this. This method aim 
to outline the most prominent SNPs for epistasis from a large feature set that can 
commonly become lost in the expanse of information. 
Concise identification of interaction combinations 
Further to the identification of SNP for epistasis, the aim of this method is to 
concisely outline combinations that show significance with the phenotype. Com-
monly many combinations will be outlined for significance with the phenotype 
due to FDR and SNP selection; the aim of this method is to combat these issues. 
4 SIMULATION RESULTS 
This section presents the results obtained using the proposed 
methodology as outlined in the previous Section 3.1.  In stage 2, 
random cohort sampling is performed for our test data. Stage 2 
provides the outcome frequencies for the subsets of individuals 
that are to be used in the following stage. 
For Stage 3, association analysis is performed using 2 different 
approaches; standard case-control and proposed random sam-
pling regularisation method. Both approaches were conducted  
using the same techniques only varying the input information. An 
allelic model, adjusted by genomic control included remaining 
subjects and SNPs from the quality control stage with variation 
conducted for the Random Sampling Regularisation approach 
using cohort samples as reported in ‘Random Cohort Sampling’. 
 
 
 
 
 
 
 
 
Figure 1: Manhattan plot for standard case-control method using allelic 
model 
 
 
 
Figure 2: Manhattan Plot generated from mean of 9 SNP p-values using 
random sampling Regularisation method scaled for comparison to Standard 
case-control 
 
Figure 1 visualises the p-values produced from an association 
analysis using standard case-control approach in a Manhattan 
plot, while Figure 6 visualises the p-values produced using the 
Random Sampling Regularisation approach. Visible is the clear 
decrease in significance for all SNPs. As the mean of 9 p-values 
for each SNP is used to create the mean p-values, any sample p-
values that show little significance for the SNP will reduce the 
mean p-value but it will reduce the presence of False Positives 
based on chance. Figure 6 is scaled to show the difference be-
tween the values generated from standard case-control process 
and random sampling regularisation method.  
Figure 3 illustrates that the consistency of the top SNPs outlined 
by standard case-control methods fluctuates across the analyses 
but present strongly when using the full cohort. 
Producing a set of representative features at stage 4 that are most 
likely to indicate the presence of a significant relationship is one 
of the main challenges of this approach. The proposed method-
ology of this research used both the standard deviation and the 
mean to produce a unique threshold that takes into consideration 
the fluctuation of values across random cohorts. Histograms in  
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Figure 3: Dot plot comparison of standard case-control vs. random sam-
pling regularisation. The difference between the values produced using 
standard case-control methods (with genomic control) (blue) , and the val-
ues produced by random sampling regularisation analysis, analysis val-
ues(black) and mean (pink).  
 
 
Figure 4: Histograms generated from association analysis using Random 
Sampling Regularisation showing A. Mean and B. Standard deviation with 
threshold exclusion measures. 
 
 
 
 
 
 
 
 
 
 
By using the standard deviation values alongside the mean, this 
approach also considers any SNPs that have an inflated mean due 
to anomaly results will be excluded based on standard deviation 
value. The purpose of this feature selection method is to produce 
a feature set that includes SNPs that show significance but more 
importantly are consistently significant regardless of the subjects 
included in the cohort. Stage 4 yielded a total of 57 features for 
further analysis. 
For stage 5, features selected using the previous process are in-
putted into software LAMPlink, using a dominant model. Link-
age Disequilibrium pruning is used to remove redundant features 
that exist as relationship as a result of high LD. A threshold, α < 
0.005 has been used for the analysis of interaction relationships. 
 
 
Figure 5: Petal plot for Interaction rs4602520; rs6910087; rs7246472 
Adjusted p-values are used to produce petal plots that show the 
significance value of each singular feature in relation to the over-
all interaction score. Figure  shows the petal plot for interaction 
rs4602520; rs6910087; rs7246472 where one of the singular 
SNPs shows a greater p-value than the combined interaction p-
value.  
In order to focus the results in this section, Table IV and Table 
VError! Reference source not found. provides the results from 
the analysis that outline any interaction combinations that pro-
duced a significant result of p-value < 0.05 from the training da-
taset. Having conducted the SNP analysis using the training data, 
the next process is to analyse the significant combinations out-
lined using a separate dataset. The purpose of this process is to 
analyse whether the significant combinations outlined retain sig-
nificance using an unused set of data which increases confidence 
in a true positive association. Table VI and Table VII provide the 
results from the testing set using all significant relationships out-
lined in Training. Combinations with NA values were omitted as 
a result of a cell frequency < 10 in a 2x2 contingency table. Com-
bination formatted in bold indicate associations that retained sig-
nificance using the testing dataset and will therefore for be car-
ried forward. 
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TABLE IV: STATISTICALLY SIGNIFICANT COMBINATION STATE FROM TRAIN-
ING SET DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Combination A: rs4602520, rs6910087, rs7246472, B: 9q21.13, 
9q21.13, C: rs4144827, rs4602520, D: 1q44, rs3924215), Vari-
ants 1: rs4602520, 2: rs6910087, 3: rs7246472, 4: rs4602520, 
rs6910087, 5: rs4602520, rs7246472, 6: rs6910087, rs7246472, 
7: rs4602520, rs6910087, rs7246472, 8: 9q21.13, 9: 9q21.13, 
9q21.13, 10: rs4144827, 11 : rs4144827, rs4602520,  12: 1q:44, 
13: rs3924215, 14: 1q:44, rs3924215) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE V: STATISTICALLY SIGNIFICANT COMBINATION STATE FROM TRAIN-
ING SET DATA CONT(1) 
 
 
 
 
(Combination: A: rs6911024, rs12170250, B: rs6852865, 
rs4602520, C: rs6852865, rs4602520, rs6910087, rs7246472, D: 
rs6852865, rs6910087, rs7246472, E: rs3924215, rs6011609, F: 
1p12, rs6011609,  G: rs4602520, rs6911024, rs7246472), (Vari-
ants: 1: rs6911024, 2: rs12170250, 3: rs6911024, rs12170250, 4: 
rs6852865, 5: rs4602520, 6: rs6852865, rs4602520, 7: 
rs6852865, 8: rs6852865, rs4602520, rs6910087, rs7246472, 9: 
rs3924215, 10: rs6011609, 11: rs3924215,rs6011609, 12: 1p12, 
13: 1p12, rs6011609,14: rs6911024, 15: rs6911024, 
rs7246472,16: rs4602520, rs6911024)     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Combination Variant/s Results 
  CI < OR > CI  OR P 
A 1 1.1567 1.2465 1.3434 1.269e-06 
2 1.4585 1.7789 2.1697 1.839e-06 
3 2.0276 2.8836 4.1010 7.567e-07 
0.7334 0.7889 0.8487 9.29e-08 
1.8680 2.7163 3.9500 1.135e-05 
B 4 1.1994 1.3135 1.4383 7.897e-07 
5 1.2529 1.3695 1.4969 6.17e-09 
6 1.2304 1.3567 1.4959 2.826e-07 
1.2360 1.3677 0.5135 3.638e-07 
0.6890 0.7494 0.8151 1.653e-08 
C 7 1.1999 1.3140 1.4390 7.597e-07 
8 2.3032 3.8322 6.3762 1.424e-05 
1.1400 1.2921 1.4644 0.0008 
1.0346 1.1485 1.2749 0.02923 
0.6850 0.7299 0.7777 4.441e-16 
1.0520 1.3280 1.6765 0.04524 
D  2.1803 3.4217 5.3699 7.129e-06 
2.2681 3.9384 6.8389 4.392e-05 
1.0970 1.2297 1.3784 0.002906 
1.0311 1.1430 1.2670 0.03282 
0.6985 0.7444 0.7934 2.531e-14 
E 9 0.7227 0.7781 0.8377 2.243e-08 
10 0.4105 0.5042 0.6193 2.643e-08 
11 0.2292 0.3538 0.5460 8.201e-05 
0.4477 0.5662 0.7160 6.7e-05 
1.2488 1.3420 1.4422 1.82e-11 
F 12 0.4018 0.4952 0.6103 3.178e-08 
13 0.0336 0.1154 0.3965 0.004002 
0.4378 0.5407 0.6678 1.66e-06 
1.6900 1.9632 2.2809 1.397e-13 
0.4266 0.5293 0.6567 1.222e-06 
G 14 1.1672 1.2583 1.3564 4.865e-07 
15 1.2947 1.5222 1.7897 1.967e-05 
0.3480 0.5345 0.8209 0.01633 
0.7941 0.8744 0.9629 0.02197 
1.2102 1.2928 1.3810 1.577e-10 
0.5920 0.7029 0.8345 0.000726
7 
0.8013 0.8712 0.9472 0.00667 
16 1.3106 1.5504 1.8341 1.762e-05 
1.2502 1.3366 1.4289 9.204e-13 
0.8054 0.8752 0.9511 0.008346 
0.5740 0.7305 0.9298 0.03229 
0.7015 0.7779 0.8625 6.293e-05 
0.5417 0.6503 0.7806 0.000106
5 
 
 
 
Combination Variant/s Results 
  CI < OR > CI  OR P 
A 1 1.2534 1.3700 1.4975 5.889e-09 
2 1.1518 1.2410 1.3372 1.955e-06 
3 1.1775 1.2811 1.3939 1.371e-06 
4 1.2964 1.5313 1.8088 2.568e-05 
1.0910 1.3880 1.7660 0.02513 
1.0355 1.1246 1.2213 0.01931 
0.7074 0.7561 0.8082 4.984e-12 
1.2726 1.5254 1.8282 0.0001259 
1.1596 1.2858 1.4256 6.228e-05 
5 1.2568 1.5436 1.8958 0.0005136 
1.2544 1.8766 2.8076 0.01016 
1.0808 1.1846 1.2984 0.002373 
0.6836 0.7329 0.7857 1.981e-13 
1.1954 1.4809 1.8346 0.002564 
1.1874 1.3105 1.4464 6.502e-06 
6 1.1737 1.2773 1.3901 1.961e-06 
1.1378 1.9779 3.4383 0.04248 
1.1807 1.3998 1.6595 0.001155 
1.0406 1.1307 1.2286 0.01494 
1.1358 1.7233 2.6149 0.03179 
1.0475 1.1537 1.2706 0.01487 
0.7299 0.7796 0.8326 4.923e-10 
7 2.1493 3.3348 5.1740 6.479e-06 
1.1074 1.7123 2.6478 0.04238 
1.0361 1.1488 1.2737 0.02712 
0.6809 0.7256 0.7733 2.22e-16 
1.9714 3.1958 5.1808 7.632e-05 
1.0411 1.2694 1.5478 0.04778 
1.1656 1.3035 1.4576 9.671e-05 
B 8 0.7107 0.7752 0.8456 1.427e-06 
8 0.6919 0.7618 0.8388 3.358e-06 
9 0.6880 0.7579 0.8350 2.492e-06 
0.7009 0.7740 0.8547 2.158e-05 
1.1787 1.2852 1.4014 1.846e-06 
C 10 1.1538 1.2961 1.4566 9.028e-06 
11 1.4425 1.8009 2.2484 1.298e-05 
0.6918 0.7442 0.8006 2.949e-11 
1.1505 1.2679 1.3973 5.887e-05 
1.0523 1.1704 1.3017 0.01496 
1.5016 1.9060 2.4194 8.643e-06 
D 12 0.7102 0.7743 0.8441 1.11e-06 
13 0.7235 0.7785 0.8377 1.893e-08 
14 0.4953 0.5863 0.6942 1.973e-07 
1.2201 1.3027 1.3908 3.11e-11 
0.4854 0.5807 0.6949 6.284e-07 
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TABLE VI: STATISTICALLY SIGNIFICANT COMBINATION STATE FROM TESTING 
SET DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(COMBINATION: A: RS4602520, RS6910087, RS7246472, B: 9Q21.13, 
9Q21.13, C: RS4144827, RS4602520, D: 1Q44, RS3924215), (VARIANTS: 1: 
RS4602520, 2: RS6910087, 3: RS7246472, 4: RS4602520, RS6910087, 5: 
RS4602520, RS7246472, 6: RS6910087, RS7246472,7:RS4602520, 
RS6910087, RS7246472, 8: 9Q21.13, 9: 9Q21.13, 9Q21.13, 10: RS4144827, 11: 
RS4144827, RS4602520, 12: 1Q:44, 13: RS3924215, 14: 1Q:44, RS3924215) 
 
 
 
 
 
 
 
 
 
 
 
TABLE VII: STATISTICALLY SIGNIFICANT COMBINATION STATE FROM TEST-
ING SET DATA CONT(1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(COMBINATION: A: RS6911024, RS12170250, B: RS6852865, RS4602520, C: 
RS6852865, RS4602520, RS6910087,   RS7246472, D: RS6852865, 
RS6910087, RS7246472, E: RS3924215, RS6011609, F: 1P12, RS6011609, G: 
RS4602520, RS6911024, RS7246472), (VARIANTS: 1: RS6911024, 2: 
RS12170250, 3: RS6911024, RS12170250, 4: RS6852865, 5: RS6852865, 
RS4602520, 6: RS6852865, 7: RS6852865, RS4602520, RS6910087, 
RS7246472, 8: RS3924215, 9: RS6011609, 10: RS3924215, RS6011609, 11: 
1P12, 12: 1P12, RS6011609, 13: RS6911024, 14: RS6911024, RS7246472, 15: 
RS4602520, RS6911024) 
 
Any combinations highlighted in grey in Table VI and Table VII 
remained significant, p < 0.05. Further information regarding the 
real-world statistical significance is shown in Table IX. 
 
 
 
 
Combina-
tion 
Vari-
ant/s 
Results 
  CI < OR > CI  OR P 
A 1 0.8492 1.0511 1.3016 0.6717 
2 1.0727 1.2425 1.4391 0.0151 
3 1.0538 1.2430 1.4661 0.0302 
4 0.9018 1.2663 1.7781 0.2526 
0.8138 1.3052 2.0931 0.3537 
1.0148 1.1918 1.3995 0.0726 
0.7422 0.8464 0.9653 0.0369 
0.9308 1.3492 1.9557 0.1845 
0.7689 0.9384 1.1452 0.5995 
5 0.3166 0.4722 0.7043 0.0020 
0.5095 1.1699 2.6866 0.7562 
0.9092 1.0881 1.3023 0.4394 
0.8012 0.9191 1.0542 0.3116 
1.2833 1.9248 2.8871 0.0079 
0.6930 0.8424 1.0239 0.1482 
6 1.0685 1.4532 1.9763 0.0456 
0.2469 0.6481 1.7015 0.4599 
1.1446 1.5972 2.2288 0.0208 
0.9611 1.1317 1.3327 0.2131 
0.6540 1.6404 4.1149 0.3760 
0.9329 1.1265 1.3603 0.2988 
0.6911 0.7875 0.8972 0.0026 
7 1.1287 2.3549 4.9131 0.0554 
0.4853 1.2741 3.3449 0.6798 
0.8281 1.0138 1.2411 0.9114 
0.7471 0.8480 0.9626 0.0323 
1.2588 2.9309 6.8239 0.0364 
0.7009 1.0675 1.6257 0.7986 
0.6465 0.8036 0.9989 0.0983 
B 8 0.7765 0.9204 1.0910 0.4225 
8 0.7921 0.9563 1.1546 0.6967 
9 0.7921 0.9567 1.1556 0.7001 
0.7971 0.9693 1.1787 0.7931 
0.9170 1.0867 1.2878 0.4205 
C 10 1.0322 1.2517 1.5178 0.0555 
11 1.2900 2.0420 3.2322 0.0106 
0.7952 0.9189 1.0620 0.3365 
0.7374 0.8914 1.0775 0.3185 
0.8605 1.0655 1.3194 0.6253 
1.2898 2.1513 3.5882 0.0138 
D 12 0.7718 0.9137 1.08178 0.3794 
13 0.8863 1.0554 1.2569 0.6114 
14 0.6751 1.0382 1.5967 0.8861 
0.8981 1.0308 1.1830 0.7176 
0.5342 0.8399 1.3206 0.5260 
 
 
Combi-
nation 
Vari-
ant/s 
Results 
  CI < OR > CI  OR P 
A 1 1.0674 1.2365 1.4325 0.0176 
2 0.7899 0.9144 1.0584 0.3143 
3 0.8285 1.0777 1.4018 0.6397 
0.4149 0.7230 1.2599 0.3368 
NA NA NA NA 
B 4 1.1999 1.3140 1.4390 7.597e-07 
5 0.8365 0.0111 1.2222 0.9239 
NA NA NA NA 
NA NA NA NA 
C 6 0.8930 1.0684 1.2783 0.5441 
7 0.8765 1.9787 4.4670 0.1681 
0.6445 0.8196 1.0422 0.1732 
0.7921 0.9567 1.1556 0.7001 
0.7459 0.8467 0.9611 0.03069 
0.4564 0.7541 1.2459 0.3552 
D  1.0589 2.2224 4.6647 0.0764 
1.3582 3.4348 8.6863 0.0287 
0.6884 0.8603 1.0752 0.2669 
0.8397 1.0257 1.2528 0.835 
0.7322 0.8312 0.9436 0.0165 
E 8 0.8863 1.0554 1.2569 0.6114 
9 0.4947 0.7347 1.0910 0.1996 
10 0.2867 0.6464 1.4575 0.3774 
0.4893 0.7675 1.2037 0.3333 
0.9853 1.1369 1.3117 0.1403 
F 11 0.2523 0.3939 0.6148 0.0006 
12 NA NA NA NA 
0.5325 0.7961 1.1904 0.3512 
1.3164 1.7737 2.3898 0.0016 
0.2694 0.4224 0.6623 0.0016 
G 13 1.0684 1.2378 1.4340 0.0171 
14 1.0473 1.4218 1.9302 0.0583 
0.2432 0.6101 1.5303 0.3768 
0.7358 0.8885 1.0729 0.3024 
1.1105 1.2653 1.4418 0.0033 
0.4618 0.6428 0.8947 0.0279 
0.7494 0.8829 1.0403 0.2116 
15 0.9217 1.2972 1.8257 0.2105 
1.0320 1.1771 1.3425 0.0414 
0.7212 0.8471 0.9950 0.0899 
0.4781 0.7668 1.2297 0.3551 
0.8740 1.0666 1.3017 0.5945 
0.4947 0.7194 1.0461 0.1480 
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Using the combinations outlined from Table VI and Table VII, 
further analysis is performed to consider their context to real-
world information. Using penetrance, incidence and risk to map 
the extent of their effect, a threshold of penetrance >60% is used 
to outlined results that present more effective significance to 
breast cancer. Table IX presents data to outline the penetrance 
and incidence of each combination. Results outlined in grey sur-
passed the threshold of 60% penetrance. 
 
TABLE IX: PENETRANCE AND INCIDENCE OF RESULT COMBINA-
TIONS 
Interaction Model Risk Pe (%) I (%) P 
rs6910087 Dominant 1.243 56.4 25.0 0.0151 
rs7246472 Dominant 1.243 54.0 18.2 0.0302 
rs4602520-rs6910087 AAAG 1.192 56.0 19.4 0.0726 
AAGG 0.846 50.8 63.1 0.0369 
rs4602520-rs7246472 Dominant 0.472 51.8 97.0 0.0020 
GAAC 1.925 67.5 3.00 0.0079 
rs6910087-rs7246472 Dominant 1.453 61.1 5.00 0.0456 
AGAC 1.597 63.3 4.00 0.0208 
GGCC 0.787 50.0 61.5 0.0026 
rs4602520, rs6910087, 
rs7246472 
AAGGCC 0.848 50.4 51.6 0.0323 
GAAGAC 2.931 76.2 0.80 0.0364 
rs4144827 Dominant 1.252 57.2 12.5 0.0555 
rs4144827-rs4602520 Dominant 2.042 68.9 2.30 0.0106 
GAGA 2.151 70.0 2.00 0.0138 
rs6852865-rs4602520-
rs6910087-rs7246472 
GGAAGG
CC 
0.847 50.3 50.5 0.0307 
rs6852865-rs6910087-
rs7246472 
AGAGAC 3.435 79.0 0.70 0.0287 
GGGGCC 0.831 50.1 52.2 0.0165 
1p12 Dominant 0.394 69.7 2.50 0.0006 
1p12-rs6011609 AAGG 1.774 52.6 95.0 0.0016 
GAGG 0.422 47.0 2.40 0.0016 
rs6911024 Dominant 1.237 56.4 25.0 0.0171 
rs6911024, rs7246472 
 
AACC 1.265 56.0 38.5 0.0030 
GAAC 0.643 52.0 96.0 0.0279 
rs4602520, rs6911024 AAAA 1.177 55.0 37.0 0.0414 
 
Table X presents the statistical characteristics of the top variants 
and interactions that were identified during this research. Figure 
6 provides a visual representation for each interaction based on 
the OR with upper and lower CI. 
 
TABLE X: PENETRANCE AND INCIDENCE OF TOP RESULT COMBINA-
TIONS 
Interaction State Risk RR Pe (%) I (%) P 
rs4602520-rs7246472 GAAC 1.925 1.119 67.5 3.00 0.0079 
rs610087-rs7246472 Dominant 1.453 1.176 61.1 5.00 0.0456 
rs6910087-rs726472 AGAC 1.597 1.219 63.3 4.00 0.0208 
rs4602520- rs610087-
rs7246472 
GAAGAC 2.931 1.460 76.2 0.80 0.0364 
rs4144827-rs4602520 Dominant 2.041 1.324 68.9 2.30 0.0106 
rs4144827-rs4602520 GAGA 2.151 1.345 70.0 2.00 0.0138 
rs6852865-rs6910087-
rs7246472 
AGAGAC 3.435 1.513 79.0 0.70 0.0287 
1p12 Dominant 0.394 0.578 69.7 2.50 0.0006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. DISCUSSION 
The proposed methodology functions as a filter, reducing the fea-
ture set through the stages performed. The first stage, QC, used 
~500K SNPs and ~28K subjects provided by the DRIVE project. 
This stage resulted in a dataset of 320,247 features and 13,649 
observations. Using the output from QC, training and testing da-
tasets were split 75:25. Random Cohort Sampling was performed 
to split the training dataset into 9 sizeable subsets of individuals 
to create a viable averaging sample size for later in further stages. 
The sample sizes were proportional in the number of cases and 
controls that were assigned to each subset.  
During the QC stage, an association analysis was performed for 
each of the 9 outlined subsets from previous stages. A further as-
sociation analysis was performed on the full data output after the 
QC stage for the purpose of a comparison with standard methods 
and was further used in the feature selection stage. The results 
from the association analysis showed a number of suggestive val-
ues within the standard GWAS approach; however there were no 
features that exceeded the genome-wide significance threshold. 
In Figure 2 
Figure  a comparison was undertaken to view the difference be-
tween the values obtained from the standard GWAS and the pro-
posed ‘random sampling regularisation’ method. This shows a 
vast difference between the values obtained by each method that 
could indicate that either the features from the standard GWAS 
are inflated or that the values from the ‘random sampling regu-
larisation’ method are extremely undervaluing the expression of 
the feature. 
During the testing phase, a large majority of the outlined combi-
nations were excluded due to low significance p-value. Pene-
trance and incidence were computed for the remaining combina-
tions to consider the real-world effect of the combination. Using 
a lenient threshold of >60%, any combinations that showed a 
penetrance greater than this threshold were outlined. Of the re-
sults, 7 interaction combinations were identified for significance 
with 1 variant expressing a protective significance. 
6. CONCLUSION 
A novel methodology was proposed that caters for the needs of 
epistasis improving flexibility and inspired by random forests 
machine learning method. The novel methodology outlined in 
this research presents a statistically conservative approach that 
Odds Ratio
10
9
8
7
6
5
4
3
2
1
0.25   0.50   0.75   1.0   1.25   1.50   1.75   2.0   2.25   2.50   2.75   3.0   3.25   3.50
>CI 6.8238
>CI 8.6863
In
te
ra
c
ti
o
n
 I
D
 
Figure 6: Odds Ratio Tree Plot for Top Results 
Od  R tio 
In
te
ra
ct
io
n
 I
D
 
10  IEEE/ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS 
 
outlines a number of interactions that present viable and reliable 
options that aim to improve reproducibility by using consistently 
transparent methods that are fully interpretable. To elaborate, the 
viability of these variants is conferred by the penetrance and risk, 
with initial results indicating its relevance using a variety of per-
mutation tests in both training and testing datasets to indicate its 
significance of <0.05. Reliability is conferred using cascading 
statistical filters that aim to investigate and reduce the candidate 
set assuming a null hypothesis. Initial results obtained via Ran-
dom Sampling Regularisation look promising but should be con-
sidered as a preliminary investigation tool. Further validation us-
ing another dataset is required to concur reliability of the results. 
While the performance of the method has been proven significant 
in this research, there still remain issues that will likely affect 
outcomes either in a lenient or conservative fashion. One of the 
most prominent issues is the balance of the standard deviation 
threshold. While the method is adaptable to specify lenient or 
conservative thresholds, it is subject to the effects of anomalous 
data points; this occurrence would present a particular problem 
in cases were the majority of data points for one variant crowd in 
a tight cluster with one data point expressing in an anomalous 
range. The difficulty in addressing this point is the removal of 
any information could be extracting from the true representation 
of the variant, or it could be aiding in presenting the true repre-
sentation of the SNP by removing the data point that has occurred 
by chance.  
Further to this, due to the nature of the method rare alleles may 
be overlooked during association analysis due to lack of support-
ing evidence in each subset. Therefore it is proposed that the out-
lined methodology would perform optimally for complex and 
common diseases. 
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